Glucagon-like peptide 1 (GLP-1) receptor agonists that reduce obesity also dial down brain inflammation, leading researchers to investigate how these agents might help treat Alzheimer’s or Parkinson’s disease. (Nature)
IV ketamine showed non-inferiority compared with IV morphine in reducing out-of-hospital traumatic pain, the KETAMORPH trial showed. (JAMA Network Open)
VX-548, an investigational selective NaV1.8 inhibitor, met its primary endpoint of reducing acute pain in phase III trials, Vertex Pharmaceuticals announced.
Memory clinic patients had higher risk for mortality than historical controls during the COVID-19 lockdown in the Netherlands. (Alzheimer’s & Dementia)
Takeda’s immune globulin infusion 10% (Gammagard liquid) was approved as an IV therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), the company said.
The first person in Neuralink’s PRIME trial had a brain-computer interface implanted, according to the company’s founder, Elon Musk. (Reuters)
The Montreal Cognitive Assessment identified people with isolated REM sleep behavior disorder who were most at risk of developing dementia with Lewy bodies. (Neurology)
Electroencephalography (EEG) microstate analysis identified different features in psychogenic nonepileptic seizures and focal epilepsy. (Epilepsia)
Researchers outlined strategies to integrate equity in neurology translational research. (Annals of Neurology)
A random sample of 1,000 sentences with the word “headache” in the mainstream media showed the term was used metaphorically half the time, which may trivialize headache disorders. (Headache)
How can CRISPR be used to treat central nervous system (CNS) disorders? (JAMA Neurology)
Please enable JavaScript to view the